AML patients with CMV reactivation (n=16) presented higher frequency of CD8+ T cells and CMV-CTL (Dextramer positive) (p=0.009, p=0.005) during the first year post-HSCT compared to patients without reactivation (n=8) (Figure 5A). Here, CD8A is linked to acute myeloid leukemia.